House Panel Advances Bill to Track ER Drug Testing, Including Marijuana

Photo by Pixabay via Pexels.

A House committee just moved a fentanyl bill forward that quietly turns into a marijuana data story once you read past the first paragraph. In mid-July 2026, the House Energy and Commerce Committee voted 46-0 to advance H.R. 2004, known as Tyler's Law, sending it toward a full House floor vote. The bill carries the name of Tyler Shamash, a 19-year-old who died in 2018 after ingesting fentanyl that hospital staff never tested for during his overdose evaluation -- a gap in emergency room protocol his family has spent years trying to close through legislation rather than lawsuits.

The headline purpose is fentanyl detection, and nobody on the committee disputed that. But buried in the bill's study requirements is a directive that reaches well beyond opioids: federal health officials would have to examine how often emergency rooms test for marijuana alongside fentanyl, amphetamines, PCP, cocaine, and opiates during overdose cases. That detail is where this story gets interesting, because it sets up a direct conflict with the Senate's companion legislation, which stripped every reference to marijuana and other non-fentanyl substances before it cleared committee earlier this year. Two chambers, two very different ideas about what belongs in a fentanyl bill.

What Tyler's Law Actually Requires

Photo by cottonbro studio via Pexels.

Rep. Ted Lieu (D-CA) introduced H.R. 2004 with a narrow, personal origin story attached to it. Tyler Shamash died after a 2018 fentanyl ingestion, and according to his family, hospital staff treating him for an apparent overdose never actually ran a test that would have confirmed fentanyl was in his system. By the time anyone identified what he'd taken, it was too late to change the outcome. That sequence -- a fatal overdose where the standard toxicology workup didn't catch the actual substance involved -- became the case for requiring a federal look at ER testing practices nationwide.

The bill itself doesn't mandate new hospital protocols directly. Instead, it requires the HHS secretary to complete a study within one year of the bill becoming law, examining how frequently emergency departments actually test for fentanyl. Critically, the study language extends the scope to cover testing frequency for amphetamines, PCP, cocaine, opiates, and marijuana during overdose evaluations, not fentanyl in isolation. That's a meaningfully broader ask than just counting fentanyl tests, since it forces HHS to produce a comparative picture of which substances hospitals routinely screen for and which ones slip through.

Before reaching the full committee, H.R. 2004 cleared the Subcommittee on Health by voice vote last month, a sign that Democrats and Republicans on the panel found little to argue about at that stage. The full committee's unanimous 46-0 tally the following month confirmed that consensus held. Unanimous votes on drug policy bills are rare enough in this Congress that they're worth noting on their own, though as the Senate side shows, that agreement doesn't extend to every chamber.

Why the Marijuana Testing Question Matters

Photo by Jess Loiterton via Pexels.

Emergency room toxicology screening isn't standardized the way most people assume. Which drugs get tested for, how quickly, and under what circumstances varies hospital to hospital, often shaped by insurance considerations, available lab equipment, and local overdose patterns rather than a uniform federal protocol. That inconsistency is part of what makes Tyler's Law's data-collection approach appealing to hospital administrators who've watched testing practices differ wildly between a rural ER and an urban trauma center handling dozens of overdose cases a week.

Marijuana's presence on that list matters for a specific reason: standard urine and blood panels frequently flag cannabis use, but marijuana is essentially never the substance causing a fatal overdose the way fentanyl is. That mismatch creates real downstream problems. When cannabis shows up on a toxicology report alongside an opioid, it can get miscast in records or public reporting as a contributing factor when it had nothing to do with the actual cause of death or the medical emergency at hand.

Advocates for cannabis policy reform argue that better federal data would help separate incidental marijuana presence from cases where it's actually driving an ER visit, cutting down on the kind of statistical noise that's long fed stigma around cannabis users caught up in unrelated overdose events. That argument lands with extra weight right now, since the federal rescheduling review of marijuana is still working its way through the regulatory process. Cleaner data on how often and why ERs even test for cannabis would give regulators, researchers, and lawmakers a firmer foundation for whatever comes out of that rescheduling decision, whenever it finally lands.

The Senate Version Tells a Different Story

Photo by Michael Judkins via Pexels.

Sen. Jim Banks (R-IN) introduced the Senate companion to Tyler's Law, and it cleared the Senate Health, Education, Labor and Pensions Committee back in January, months ahead of the House vote. On paper, it looks like the same bill. In practice, it isn't anymore.

Before passage, the Senate HELP Committee adopted an amendment stripping out marijuana along with the other non-fentanyl substances named in the House version. What started as a multi-substance study got narrowed down to fentanyl and fentanyl alone. The Senate bill also gives HHS three years to complete its study, compared to the House's one-year deadline -- a longer runway for a narrower task, which is an odd pairing if the goal were simply thoroughness rather than a deliberate scaling-back of ambition.

That combination -- less substance, more time -- tells you something about where Senate Republicans wanted this legislation to sit. Framing Tyler's Law strictly around fentanyl keeps the bill politically uncomplicated: nobody in either party wants to be seen slow-walking fentanyl testing reform, especially with a name and a face attached to the bill's origin story. Folding marijuana, cocaine, and amphetamines into the same study invites exactly the kind of drug-policy debate that Senate committee leadership apparently wanted to avoid attaching to a bill built around a teenager's death. The House, by contrast, treated the broader substance list as a reasonable extension of the same underlying problem: hospitals not testing consistently for what actually shows up in overdose cases. That's the gap that will need resolving before this bill can reach a president's desk in identical form.

A Separate Bill Targets Marijuana and Medicaid Costs

Photo by SHVETS production via Pexels.

Tyler's Law isn't the only marijuana-adjacent health data bill moving through Congress this year. Sens. Ted Budd (R-NC) and Pete Ricketts (R-NE) introduced S.4345, the Marijuana Impact on Medicaid Act of 2026, in April, taking a more direct swing at cannabis specifically rather than folding it into a broader overdose-testing framework.

The bill would require HHS to compile combined federal and state Medicaid spending tied to inpatient, outpatient, and emergency room care connected to marijuana use. It's now sitting with the Senate Finance Committee, and if it advances, HHS would owe a report within one year of enactment, with the option to attach policy recommendations based on what the spending data shows. The pitch from Budd and Ricketts is straightforward: Medicaid programs are footing a bill for marijuana-related health complications, and nobody in Washington currently has a clean national number for what that actually costs.

None of this is new territory for Budd specifically. The language in S.4345 closely mirrors amendments he's floated before, none of which ever got a floor vote in the Senate. Whether this version fares differently likely depends on whether Finance Committee leadership decides Medicaid cost data is worth prioritizing this session.

Zoom out and a pattern comes into focus. In June, House Appropriations action preserved federal drug-testing rules for government employees regardless of what happens with marijuana rescheduling, another sign that Congress wants its own data infrastructure and workplace policies to keep functioning independently of whatever the DEA eventually decides. Between Tyler's Law, the Medicaid cost study, and the appropriations language, 2026 is shaping up as the year Congress decided it wanted harder numbers on marijuana's footprint in the health system, whichever direction those numbers ultimately point.

Strip away the shared name and shared origin story, and the House and Senate versions of Tyler's Law reveal two fundamentally different instincts about where marijuana belongs in federal drug policy data. The House sees cannabis as one substance among several worth tracking alongside fentanyl, useful context for understanding what's actually happening in an ER during an overdose. The Senate, at least in its committee-passed form, would rather keep the bill narrowly about the opioid that's driving the overdose crisis and leave marijuana out of it entirely.

That gap has to close somewhere before Tyler's Law can become law in a form both chambers agree on, and conference negotiations are where it'll likely get resolved -- or where the bill stalls. Cannabis-related provisions are the obvious sticking point, since fentanyl testing itself has bipartisan support that isn't really in question. The one-year versus three-year study deadline is a secondary issue that negotiators can probably split the difference on without much drama.

Whatever happens to this particular bill, the underlying interest isn't going away. Between Tyler's Law's testing study, Budd and Ricketts' Medicaid cost bill, and this year's appropriations language locking in federal workplace drug-testing rules independent of rescheduling, Congress has made clear it wants better data on marijuana's presence in emergency care and public health spending. Hospitals, state Medicaid programs, and cannabis policy advocates alike should plan on that scrutiny continuing regardless of how the rescheduling process ultimately resolves.